TrialEfficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
Trial details
- Registry ID
- NCT05415137
- Phase
- Phase 3
Drug research
Efzofitimod 3 mg/kg
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as ATYR1923; KRP-R120
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary SarcoidosisNCT05415137 | ATYR | Phase 3 | Completed | 2025-06-25Actual |
| Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19NCT04412668 | ATYR | Phase 2 | Completed | 2020-10-23Actual |
Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19
Trial details
- Registry ID
- NCT04412668
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |